![](http://bsg-s.nbxc.com/site_themes/common/inquiry_popup/images/close.png)
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Gilead 's New Morea Vemlidy (Tenofovir Alafenamide Fumarate, 25mg, 일단 25mg)는 보상 간 질환에서 만성 B 형 간염 바이러스 감염을 위해 미국 FDA가 승인했습니다. Vemlidy는 혁신적인 타겟 Tenofovir 프로 드러그입니다. 이전 제품 VIREAD (Tenofovir Disoproxil Fumarate, Tenofovirdisoproxilfumarate) 300mg에 비해 복용량의 1/10 미만 만 필요합니다. 유사한 항 바이러스 효과를 얻으십시오.
제품 디렉토리 : API 중간체 > 테노포비르 알라페나미드 푸마레이트 중간체
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.